恆指跌幅擴至逾300點 友邦、港交所、網易、聯想集團挫4.5%至7% 藥明生物瀉12%
美股期貨全面跌約0.2%,亞太區主要股市今早(5日)全面向下,日經及澳洲200指數分別續跌1.4%及回吐1.1%;滬指及深成續跌0.7%至0.9%。
標普全球香港11月PMI重現溫和擴張,由10月48.9,回升至50.1。然而,恆指三連跌兼屢創逾一年低,今早低開39點或0.2%,報16,606欠承接,最低見16,332,現報16,338,下挫307點或1.8%,總成交額563億元。此外,科指續挫2.2%報3,675。
藍籌股普遍下跌,藥明生物(02269.HK)強調集團業務營運及財務狀況維持強勁勢頭,兼且業務營運及財務狀況並未發生重大不利變動,但遭多間大行削價。該股今天復牌,曾跌見29.05元,創逾三年半低,現報29.11元,續挫12.2%。同系「藍籌新貴」藥明康德(02359.HK)續跌3%報80.95元。
金融股港交所(00388.HK)沽壓最大,今早低見252.2元,屢創逾一年低,最現報255.4元,續挫4.8%。友邦保險(01299.HK)最低見63.1元,創逾兩個月低,現報63.25元,續跌4.5%。
聯想集團(00992.HK)主席楊元慶行使股份增值權及減持,其持股量降至7.66%,該股由逾兩年半高位回落,重失10天及20天線,最低見9.08元,現報9.19元,回吐7%。
內房股中海外(00688.HK)及龍湖(00960.HK)跌2.6%及3.4%,報13.58元(近十四年低)及12.9元。
騰訊(00700.HK)、百度-SW(09888.HK)、舜宇(02382.HK)及網易-S(09999.HK)挫逾2.5%至5%;前者現報308.6元,後者沽壓最大報157.9元,續挫5.2%。
美團-W(03690.HK)及海底撈(06862.HK)續跌2.9%至4.2%,報83.95元及14.06元,再創52周低。百威亞太(01876.HK)挫4.6%報12.78元創上市新低。此外,中國宏橋(01378.HK)挫5.2%,報5.7元創約五個月低。
然而,比亞迪(01211.HK)及金沙中國(01928.HK)逆市續升1.5%至1.7%,分別報209.6元及20.4元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.